U.S. markets open in 8 hours 14 minutes

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.79-0.11 (-1.59%)
At close: 04:00PM EDT
6.66 -0.13 (-1.91%)
After hours: 04:31PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close6.90
Bid0.00 x 800
Ask0.00 x 1000
Day's Range6.67 - 6.92
52 Week Range6.67 - 28.25
Avg. Volume1,026,030
Market Cap323.91M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-3.87
Earnings DateOct 31, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for QURE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • uniQure N.V.
    QURE: Lowering target price to $8.00UNIQURE NV has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    16 days agoArgus Research
View more
  • Motley Fool

    Why Shares of uniQure Are Dropping Tuesday

    Shares of uniQure (NASDAQ: QURE) were down more than 11% as of 1:06 p.m. on Tuesday after the gene-therapy company announced that the Food and Drug Administration (FDA) had cleared its investigational new drug (IND) application for AMT-260, a treatment for refractory mesial temporal lobe epilepsy (MTLE). The disease is a chronic neurologic disorder, considered the most common form of focal epilepsy (which affects one side of the brain). At one point on Tuesday morning, the stock fell to a 52-week low of $7.40.

  • GlobeNewswire

    uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

    Clinical trial initiation expected in the fourth quarter of 2023LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy (MTLE). AMT-260

  • PR Newswire

    Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P 100, S&P MidCap 400 and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more repres